1.郑毅，胡佩诚.儿童心理保健与咨询-培训教材.北京：人民卫生出版社，2012：11-20.

2.郭兰婷.儿童少年精神病学.北京：人民卫生出版社，2009.

3.桂永浩，薛辛东.儿科学.第3版.北京：人民卫生出版社，2015：401-403.

4.李凌江.精神病学.第3版.北京：人民卫生出版社，2015：232-255.

5.郝伟.精神病学.第7版.北京：人民卫生出版社，2013.

6.TasseMJ，Luckasson R，Nygren M.Intellectual and Developmental Disabilities，2013，51（2）：127-131.

7.Lloyd BP，Kennedy CH.Journal of Applied Research in Intellectual Disabilities，2014，27：187-199.

8.Antonio P，Mariangela M，Sara S，et al.Oxytocin andAutism：A Systematic Review of Randomized Controlled Trials.Journal of Child and Adolescent Psychopharmacology，2014，24（2）：54-68.

9.Barger BD，Campbell JM，McDonough JD.Prevalence and onset of regression within autism spectrum disorders：ametaanalyticreview.JAutismDev Disord，2013，3（4）：817-828.

10.Brondino N，Fusar-Poli L，Rocchetti M，et al.Complementary and Alternative Therapies for Autism Spectrum Disorder.Evid Based Complement Alternat Med，2015：258589.

11.CristanF，Audrey T and Paul G.Pharmacotherapy for the Core Symptoms in Autistic Disorder：Current Status of the Research.Drugs，2013，73（4）：303-314.

12.Dwayne D，Zachary W，Melissa LM，et al.Medications for Adolescents and Young Adults With Autism Spectrum Disorders： A Systematic Review.Pediatrics， 2012， 130：717-726.

13.Gjevik E，Eldevik S，Fjæran-Granum T，et al.Kiddie-SADS reveals high rates of DSM-IV disorders in children and adolescents with autism spectrum disorders.J Autism Dev Disord，2011，41（6）：761-769.

14.Jaiswal P，Mohanakumar KP，Rajamma U.Serotonin mediated immunoregulation and neural functions：Complicity in the aetiology of autismspectrum disorders.Neurosci Biobehav Rev.，2015，55：413-431.

15.Kulage KM，Smaldone AM，Cohn EG.How will DSM-5 affect autism diagnosis Asystematicliteraturereview andmeta-analysis.JAutismDev Disord.， 2014， 44（8）：1918-1932.

16.Mandy W，Lai MC.Annual Research Review：The role of the environment in the developmental psychopathology of autism spectrum condition.J Child Psychol Psychiatry，2016，57（3）：271-292.

17.National Autism Center.Findings and conclusions：National standards project，phase 2.Randolph，MA：Author.

18.NatasciaBrondino，Laura Fusar-Poli，Matteo Rocchetti，et al.Complementary and Alternative Therapies for Autism Spectrum Disorder.Evidence-Based Complementary and Alternative Medicine，2015：31.

19.Ornoy A，Weinstein-Fudim L，Ergaz Z.Prenatal factors associated with autism spectrum disorder（ASD）.Reprod Toxicol，2015，56：155-169.

20.Ruth CM.Philip，Maria R.Dauvermann，Heather C.Whalley，et al.A systematic review and Meta-analysis of the fMRI investigation of autism spectrum disorders.Neuroscience and Biobehaviral Reviews，2016，32：901-942.

21.Sampathkumar Rangasamy&Santosh R.D’Mello&Vinodh-Narayanan.Epigenetics，Autism Spectrum，and Neurodevelopmental Disorders，Neurotherapeutics，2013，10：742-756.

22.Taurines R1，Schwenck C，Lyttwin B，et al.Oxytocin plasma concentrations in children and adolescents with autism spectrum disorder：correlation with autistic symptomatology.Atten Defic Hyperact Disord.2014，6（3）：231-9.

23.Tsai Luke Y.Asperger's disorder will be back.J of autism and developmental disorders，2013，2914-42.

24.Sue woolfenden，Vanessa Sarkozy，Greta Ridley，et al.A systematic review of the diagnostic stability of autism spectrum disorders.Research in autism spectrum disorders，2012，6：345-354.

25.郭延庆.应用行为分析与儿童行为管理.北京：华夏出版社，2012.

26.Barrickman，L.L.，et al.，Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder.J Am Acad Child Adolesc Psychiatry，1995.34（5）：649-57.

27.Biederman J，Spencer T，Wilens T.（2004），Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder.Int J Neuropsychopharmacol 7：77-97.

28.Brookes KJ，Chen W，Xu XH，et al.（2006）：Association of fatty acid desaturase genes with attention-deficit/hyperactivity disorderhuman FADS2 gene.Biological Psychiatry.60（10）：1053-1061.

29.Casat，C.D.，D.Z.Pleasants and F.J.Van Wyck，A doubleblind trial of bupropion in children with attention deficit disorder.Psychopharmacol Bull，1987.23（1）：120-2.

30.Casat， C.D.， et al.， Bupropion in children with attention deficit disorder.Psychopharmacol Bull， 1989.25（2）：198-201.

31.Conners，C.K.，et al.，Bupropion hydrochloride in attention deficit disorderwith hyperactivity.JAm Acad Child Adolesc Psychiatry，1996.35（10）：1314-21.

32.Dickstein SG，Bannon K，Xavier Castellanos F，Milham MP（2006）：The neural correlates of attention deficit hyperactivity disorder：an ALE meta-analysis. J Child Psychol Psychiatry， 47：1051-62.

33.Faraone SV，Sergeant J，Gillberg C，Biederman J（2003）：The worldwide prevalence of ADHD：Is it an American condition？ World Psychiatry 2：104-113.

34.Faraone，S.V.，T.Spencer，et al.（2004）."Meta-analysis of the efficacy of methylphenidate for treating adult attentiondeficit/hyperactivity disorder."J Clin Psychopharmacol 24（1）：24-9.

35.Faraone SV，Perlis RH，Doyle AE，Smoller JW，Goralnick JJ，Holmgren MA，Sklar P（2005）：Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 57（11）：1313-23.

36.Faraone，S.V.，et al.，Long-term effects of extended-release mixed amphetamine salts treatment of attention-deficit/hyperactivity disorder on growth.J Child AdolescPsychopharmacol，2005.15（2）：191-202.

37.Graetz，B.W.，M.G.Sawyer and P.Baghurst，Gender differences among children with DSM-IV ADHD in Australia.J Am Acad Child Adolesc Psychiatry，2005.44（2）：159-68.

38.Haslam，N.，et al.，The latent structure of attention-deficit/hyperactivity disorder：a taxometric analysis.Aust N Z J Psychiatry，2006.40（8）：639-47.

39.Kustanovich V，Ishii J，Crawford L，Yang M，McGough JJ，McCracken JT，et al.（2003）：Transmission disequilibrium testing of dopamine-related candidate gene polymorphisms in ADHD：Confirmation of association of ADHD with DRD4 and DRD5. Mol Psychiatry 9：711-717.

40.Kustanovich V，Merriman B，McGough J，McCracken JT，Smalley SL，　Nelson SF　（2003b：　Biased paternal transmission of SNAP-25 risk alleles in attention-deficit hyperactivity disorder. Mol Psychiatry 8：309-315.

41.Guan Let al.A high-density single-nucleotide polymorphism screen of 23 candidate genes in attention deficit hyperactivity disorder：suggesting multiple susceptibility genes among Chinese Han population. Mol Psychiatry.2009；14（5）：546-554.

42.Li H，L et al.Sex-specific association of brain-derived neurotrophic factor（BDNF）Val66Met polymorphism and plasma BDNF with attention-deficit/hyperactivity disorder in a drug-naive Han Chinese sample. Psychiatry Res.2014；217（3）：191-197.

43.Liu L et al.Association between SYP with attention-deficit/hyperactivity disorder in Chinese Han subjects：Differences among subtypes and genders. Psychiatry Res.2013；210（1）：308-14.

44.Liu L et al.BAIAP2 exhibits association to childhood ADHD especially predominantly inattentive subtype in Chinese Han subjects. Behav Brain Funct.2013； 9： 48.doi：http：//dx.doi.org/10.1186/1744-9081-9-48.

45.Qian Y et al.Do executive function deficits differentiate between children with attention deficit hyperactivity disorder（ADHD）and ADHD comorbid with oppositional defiant disorder？A cross-cultural study using performance-based testsand the behaviorrating inventory ofexecutive function. Clin Neuropsychol.2010；24（5）：793-810.

46.Guan Let al.A high-density single-nucleotide polymorphism screen of 23 candidate genes in attention deficit hyperactivity disorder：suggesting multiple susceptibility genes among Chinese Han population. Mol Psychiatry.2009；14（5）：546-554.

47.Li H，Let al.Sex-specific association of brain-derived neurotrophic factor（BDNF）Val66Met polymorphism and plasma BDNF with attention-deficit/hyperactivity disorder in a drug-naive Han Chinese sample. Psychiatry Res.2014；217（3）：191-197.

48.Liu Let al.Association between SYP with attention-deficit/hyperactivity disorder in Chinese Han subjects：Differences among subtypes and genders. Psychiatry Res.2013；210（1）：308-14.

49.Liu L et al.BAIAP2 exhibits association to childhood ADHD especially predominantly inattentive subtype in Chinese Han subjects. Behav Brain Funct.2013； 9： 48.doi：http：//dx.doi.org/10.1186/1744-9081-9-48.

50.Qian Y et al.Do executive function deficits differentiate between children with attention deficit hyperactivity disorder（ADHD）and ADHD comorbid with oppositional defiant disorder？A cross-cultural study using performance-based testsand the behaviorrating inventoryofexecutive function. Clin Neuropsychol.2010；24（5）：793-810.

51.Shuai L et al.Executive function profile of Chinese boys with attention-deficit hyperactivity disorder：different subtypes and comorbidity. Arch Clin Neuropsychol.2011；26（2）： 120-132.doi： http：//dx.doi.org/10.1093/arclin/acq101.

52.Ji Net al.Dopamine beta-hydroxylase gene associates with Stroop color-word task performance in Han Chinese children with attention deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet.2011；156B（6）：730-736.

53.Qian QJ et al.Gene-gene interaction between COMT and MAOA potentially predicts the intelligence of attention-deficit hyperactivity disorder boys in China. Behav Genet.2010；40（3）：357-365.

54.Liu Let al.Association between SYP with attention-deficit/hyperactivity disorder in Chinese Han subjects：Differences among subtypes and genders. Psychiatry Res.2013；210（1）：308-14.

55.Yang L et al.Polygenic transmission and complex neuro developmental network for attention deficit hyperactivity disorder：genome-wide association study of both common and rare variants. Am J Med Genet B Neuropsychiatr Genet.2013；162B（5）：419-430.

56.Yang L et a，.Association of norepinephrine transporter gene with methylphenidate response. J Am Acad Child Adolesc Psychiatry.2004；43（9）：1154-1158.

57.Yang L et a.Adrenergic neurotransmitter system transporter and receptor genes associated with atomoxetine response in attention-deficit hyperactivity disorder children. J Neural Transm.2013；120（7）：1127-1133.

58.Ji Net al.Dopamine beta-hydroxylase gene associates with Stroop color-word task performance in Han Chinese children with attention deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet.2011；156B（6）：730-736.

59.Qian QJ et al.Gene-gene interaction between COMT and MAOA potentially predicts the intelligence of attention-deficit hyperactivity disorder boys in China.Behav Genet.2010；40（3）：357-365.

60.Liu L et al.Association between SYP with attention-deficit/hyperactivity disorder in Chinese Han subjects：Differences among subtypes and genders.Psychiatry Res.2013；210（1）：308-14.

61.Yang L et al.Polygenic transmission and complex neuro developmental network for attention deficit hyperactivity disorder：genome-wide association study of both common and rare variants.Am J Med Genet B Neuropsychiatr Genet.2013；162B（5）：419-430.

62.Yang L et al，.Association of norepinephrine transporter gene with methylphenidate response.J Am Acad Child Adolesc Psychiatry.2004；43（9）：1154-1158.

63.Yang L et al.Adrenergic neurotransmitter system transporter and receptor genes associated with atomoxetine response in attention-deficit hyperactivity disorder children.J Neural Transm.2013；120（7）：1127-1133.

64.Michelson，D.，et al.，Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder： a randomized， placebo-controlled， dose-response study.Pediatrics，2001.108（5）：E83.

65.Polanczyk，G.，et al.，The worldwide prevalence of ADHD：a systematic review and metaregression analysis.Am J Psychiatry，2007.164（6）：942-8.

66.Polderman，T.J.，et al.，Across the continuum of attention skills：a twin study of the SWAN ADHD rating scale.J Child Psychol Psychiatry，2007.48（11）：1080-7.

67.Quinn，P.O.and J.L.Rapoport，One-year follow-up of hyperactive boys treated with imipramine or methylphenidate.Am J Psychiatry，1975.132（3）：241-5.

68.Ross， D.C.， J.Fischhoff and B.Davenport， Treatment of ADHD when tolerance to methylphenidate develops.Psychiatr Serv，2002.53（1）：102.

69.Swanson，J.，et al.，Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children.Clin Pharmacol Ther，1999.66（3）：295-305.

70.Swanson，J.M.，et al.，Secondary evaluations of MTA 36-month outcomes：propensity score and growth mixture model analyses.J Am Acad Child Adolesc Psychiatry，2007.46（8）：1003-14.

71.Swanson JM，et al.Effects of stimulant medication on growth rates across 3 years in the MTA follow-up.J Am Acad Child Adolesc Psychiatry，2007.46（8）：1015-27.

72.Swanson JM，et al.DSM-V and the future diagnosis of attention-deficit/hyperactivity disorder.Curr Psychiatry Rep，2009.11（5）：399-406.

73.Spencer TJ，et al.Journal of Clinical Psychiatry，2013；74，902-917.

74.Shulz KP，et al.（2012）.Archives of Psychiatry，2013；69（9），952-961.

75.Frodl FT， &Skokauskas Acta PsychiatricaScandinavica，2012；125，114-126.

76.Kasparek T，Theiner P，Filova A.Neurobiology of ADHD From Childhood to Adulthood：Findings of Imaging Methods[J].J Atten Disord，2013.

77.Stahl SM，et al.Stahl’s Essential Psychopharmacology.New York，Cambridge University Press.3rd ed.2008.P867.

78.Nakao et al.，Am J Psychiatry 2011，168，1154.

79.Frodl et al.，Acta Psychiatr Scand 2012：125：114-126.

80.Shaw et al.Am J Psychiatry 2009；166：58-63.

81.Wu Z，Yang L，Wang Y.Applying imaging genetics to ADHD：the promises and the challenges.Mol.

82.Tannock R.Attention Deficit Hyperactivity Disorder：Advances in Cognitive，　Neurobiological，　and Genetic Research.J Child PsysholPsychiat 1998；39：65-99.

83.Valera EM，Faraone SV，Murray KE，Seidman LJ（2006）：Meta-analysis of structural imaging findings in attentiondeficit/hyperactivity disorder.Biol Psychiatry，52：785-794.

84.Van der Oord，S，et al.，Efficacy of methylphenidate，psychosocial treatments and their combination in school-aged children with ADHD：a meta-analysis.Clin Psychol Rev，2008.28（5）：783-800.

85.Volkow， N.D.， et al.， Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain.J Neurosci，2001.21（2）：RC121.

86.Volkow，N.D.，et al.，Evaluating dopamine reward pathway in ADHD：clinical implications.JAMA，2009.302（10）：1084-91.

87.Wang Y et ai，.Atomoxetine versus methylphenidate in pediatric outpatients with attention-deficit/hyperactivity disorder：a randomized，double-blind comparison trial.Aust N Z J Psychiatry 2007；41（3）：222-230.

88.Waschbusch，D.A.and S.King，Should sex-specific norms be used to assess attention-deficit/hyperactivity disorder or oppositional defiant disorder？.J Consult Clin Psychol，2006.74（1）：179-85.

89.杜亚松.儿童心理障碍诊疗学，人民卫生出版社，北京，2013，468-479.

90.American Psychiatric Association.Diagnostic and Statistical ManualofMentalDisorders， Fifth Edition， DSM-5.American Psychiatric Publishing，Washington DC，2013.

91.Weele JVV，Warren Z.Social communication deficits in the general population：how far out does the autism spectrum go.J Am Acad Child Adolesc Psychiatry，2011；50（4）：326-328.

92.Swineford LB，Thurm A，Baird G，et al.Social（Pragmatic）communication disorder：a research review of this new DSM-5 diagnostic category，Journal of Neurodevelopmental Disorders，2014；6：41.

93.Adams C，Lockton E，Freed J，et al.Effectiveness of a Social Communication Intervention，International Journal of Language&Communication Disorders，2012；47：233-244.

94.Tufan E.the relationship between social communication disorder（SCD）and broad autism phenotype（BAP），J Am Acad Child Adolesc Psychiatry，2014；53（10）：1130.

95.杜亚松.儿童心理障碍诊疗学，人民卫生出版社，北京，2013，247-277.

96.杨斌让.特定学习障碍.中华实用儿科临床杂志，2015；30（11）：810-817.

97.American Psychiatric Association.Diagnostic and Statistical Manual of Mental Disorders，Fifth Edition，DSM-5.American Psychiatric Publishing，Washington DC，2013.

98.Brkanac Z，Myers K.Specific Learning Disabilities and Difficulties in children and Adolescents：Psychological Assessment and Evaluation，J Am Acad Child Adoles Psychiatry，2003；42（1）：121-122.

99.James F Leckman and Donald J.Cohen.Tic disorders：Child and Adolescent Psychiatry.Edited by Michael Rutter and Eric Taylor.Blackwell Publising2005，593-611.

100.郑毅.抽动障碍理论与实践进展.儿童青少年精神病学新进展.中国协和医科大学出版社.2010；260-272.

101.程宇航，郑毅，王力芳，等.抽动秽语综合征的多巴胺D4受体基因多态性分析.中华检验医学杂志，2003；26（1）：40-41.

102.程宇航，何凡，郑毅.Tourettes＇综合征患者血清脑源性神经营养因子表达水平对照研究.精神病学杂志2010；23（4）：248-249.

103.刘寰忠，郑毅，崔永华.抽动秽语综合征患者血清免疫球蛋白、C反应蛋白测定的对照研究.安徽医学，2005；26（3）：170-172.

104.Cheng YH，Zheng Y，He F，etc.Detection of Autoantibodies and Increased Concentrations of Interleukins in Plasma from Patients with Tourette's Syndrome.J Mol Neurosci.2012 Sep；48（1）：219-24.

105.朱焱，王凯，张纪水等.长沙市一所小学和中学6-15岁学龄儿童抽动障碍现状调查.中国心理卫生杂志，2003；17（6）：363-366.

106.刘永翼，郑毅，韩书文等.北京市大兴区学龄儿童抽动障碍相关危险因素的病例对照研究.中国心理卫生杂志，2010；24（1）：47-50.

107.郑毅.关注注意缺陷多动障碍的共患病.中华儿科杂志，2010，48（5）：325-328.

108.钟佑泉，周文智，胡文广等.可乐定透皮贴剂治疗儿童抽动障碍的随机双盲对照研究.中华儿科杂志，2007；45（10）：785-787.

109.郑毅，梁月竹，杨建虹，等.丙戊酸钠合并氟哌啶醇治疗难治性 TS.中华精神科杂志，2001，34：83-85.

110.崔永华，郑毅，刘寰忠.难治性抽动秽语综合征的临床特点.上海精神病学，2005，17（1）：13-17.

111.崔永华，郑毅.影响利培酮治疗Tourette综合征疗效的多因素分析.中华精神科杂志，2006，39（2）：98-101.

112.Cui YH，Zheng Y，Yang YP，et al.Effectiveness and Tolerability of Aripiprazole in Children and Adolescents with Tourette Disorder------A pilot study in China.Journal of Child and Adolescent Psychopharmacology，2010：20（4）：291-298.

113.郑毅，刘靖主编.中国注意缺陷多动障碍防治指南（第二版）.中华电子音像出版社 2015：1-5；63-69.

114.Zheng Y，Zhang ZJ，Han XM，et al.A proprietary herbal medicine（5-Ling Granule）for Tourette syndrome：a randomized controlled trial.Journal of Child psychology and psychiatry.2015，57（1）；74-83.

115.Sadock BJ，Sadock VA，Ruiz P.Kaplan and Sadock's Synopsis ofPsychiatry：BehavioralScience/Clinical Psychiatry（11th edition）.Philadelphia：Lippincott Williams and Wilkins，2014.

116.American Psychiatric Association.Diagnostic and Statistical Manual of Mental Disorders（5th edition）.Washington，DC：American Psychiatric Publishing，2013.

117.Barry S，Baird G，Lscelles K，et al.Neurodevelopmental movement disorders-an update on childhood motor stereotypies.Developmental Medicine and Child Neurology，2011，53（11）：979-985（7）.

118.Cheng HC，Chen JY，Tsai CL，et a1.Reading and writing performances of children 7-8 years of age with developmental coordination disorder in Taiwan[J].Res Dev Disabil，2011，32：2589-2594.

119.Fazzia E，Lannersb J，Danovaa S，et al.Stereotyped behaviours in blind children.Brain and Development，1999，21（8）：522-528.

120.花静，孟炜，吴擢春等.苏州城区幼儿园学龄前儿童发育性运动协调障碍的环境影响因素研究，中华儿科杂志，2014，52（8）：590-595.